NCT07268638Phase 2Recruiting

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Study sponsor: Akebia Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants60Estimated
Source updated2026-11-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from Baseline in urine protein-to-creatinine ratio (UPCR) Time frame: Baseline (Day 1) and up to Week 24. After: Measure: Change from Baseline in urine protein-to-creatinine ratio (UPCR) (Part A) Time frame: Baseline (Day 1) and up to Week 24 Measure: Proportion of participants with TEAEs, serious adverse events (SAEs), and treatment-emergent adverse events of special interest (AESIs). (Part A) Time frame: Time Frame: Up to Week 52.

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source